Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Barclays PLC

Barclays PLC grew its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 65.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,658 shares of the company’s stock after purchasing an additional 31,527 shares during the period. Barclays PLC owned 0.15% of Kodiak Sciences worth $208,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Kodiak Sciences by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock worth $2,007,000 after acquiring an additional 12,783 shares during the period. State Street Corp lifted its holdings in shares of Kodiak Sciences by 1.8% during the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after acquiring an additional 14,711 shares during the period. FMR LLC lifted its holdings in shares of Kodiak Sciences by 26.4% during the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after acquiring an additional 41,987 shares during the period. LJI Wealth Management LLC lifted its holdings in shares of Kodiak Sciences by 21.3% during the 3rd quarter. LJI Wealth Management LLC now owns 17,100 shares of the company’s stock worth $45,000 after acquiring an additional 3,000 shares during the period. Finally, RIA Advisory Group LLC purchased a new position in shares of Kodiak Sciences during the 3rd quarter worth about $191,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Price Performance

Kodiak Sciences stock opened at $7.50 on Wednesday. The company has a market cap of $394.65 million, a PE ratio of -2.05 and a beta of 2.11. The company has a fifty day moving average price of $7.98 and a two-hundred day moving average price of $4.72. Kodiak Sciences Inc. has a 12 month low of $2.18 and a 12 month high of $11.60.

Analysts Set New Price Targets

Several research analysts recently commented on KOD shares. HC Wainwright restated a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a report on Friday, November 15th. Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Monday, December 9th. Finally, Barclays raised their price target on shares of Kodiak Sciences from $3.00 to $4.00 and gave the company an “underweight” rating in a report on Friday, November 15th.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.